The IPO Buzz: Evommune (EVMN) Prices IPO at $16 – Mid-Point
Evommune (EVMN), a Phase II biotech developing treatments for atopic dermatitis and ulcerative colitis, priced its IPO at $16.00 – the mid-point of its $15.00-to-$17.00 price range -on Wednesday night, Nov. 5, 2025. The California company sold 9.38 million shares – the number of shares in the prospectus – and raised $150 million in its […]
November 5, 2025 Read More